J&J: completes acquisition of Abiomed

(CercleFinance.com) - Johnson & Johnson announced that it has completed the acquisition of Abiomed last night.


The company will now operate as a stand-alone business within Johnson & Johnson's MedTech segment.

It said that this is another key step in Johnson & Johnson's path to accelerate the growth of its MedTech business and bring innovative medical technologies to more people worldwide.

Johnson & Johnson's tender offer for all outstanding shares of Abiomed for an initial payment of $380 per share - representing an enterprise value of about 16.6 billion dollars - expired on 21 December 2022.

Abiomed shareholders will also receive a non-negotiable contingent value right ("CVR") entitling the holder to receive up to 35 dollars per share in cash if certain commercial and clinical milestones are achieved.


Copyright (c) 2022 CercleFinance.com. All rights reserved.